Managing Clostridium difficile in Inflammatory Bowel Disease (IBD)

被引：21

作者：

Hashash J.G. ^{[1
]}

Binion D.G. ^{[1
]}

机构：

[1] Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15213

来源：

Current Gastroenterology Reports | 2014年 / 16卷 / 7期

关键词：

C. difficile infection; Fecal microbiome transplant; IBD; Inflammatory bowel disease; Metronidazole; Vancomycin;

D O I：

10.1007/s11894-014-0393-1

中图分类号：

学科分类号：

摘要：

Clostridium difficile (C. difficile) infection has emerged as a significant clinical challenge for patients suffering from inflammatory bowel disease (IBD). C. difficile can both precipitate and worsen flares of IBD, contributing to emergent colectomies and mortality. Advances in the management of C. difficile infection in IBD include recommendations for testing for this infection in the setting of clinical flare and hospitalization, improved diagnostic testing, identification of high rates of carriage and infection in pediatric IBD, and new data associating patterns of IBD genetic risk alleles with the development of this infection. Therapeutically, oral vancomycin has emerged as a superior treatment for IBD patients with moderate to severe disease compared with metronidazole. Although highly effective in the general population, fecal microbiome transplantation for recurrent C. difficile infection in IBD patients has been associated with colitis flare in the majority of patients who have received this treatment. © Springer Science+Business Media 2014.

引用

共 28 条

[1]

Kelly C.P., LaMont J.T., Clostridium difficile - More difficult than ever, N Engl J Med, 359, 18, pp. 1932-1940, (2008)

[2]

Rodemann J.F., Dubberke E.R., Reske K.A., Seo D.H., Stone C.D., Incidence of Clostridium difficile Infection in Inflammatory Bowel Disease, Clinical Gastroenterology and Hepatology, 5, 3, pp. 339-344, (2007)

[3]

Issa M., Vijayapal A., Graham M.B., Beaulieu D.B., Otterson M.F., Lundeen S., Skaros S., Weber L.R., Komorowski R.A., Knox J.F., Emmons J., Bajaj J.S., Binion D.G., Impact of Clostridium difficile on Inflammatory Bowel Disease, Clinical Gastroenterology and Hepatology, 5, 3, pp. 345-351, (2007)

[4]

Ananthakrishnan A.N., McGinley E.L., Binion D.G., Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease, Gut, 57, 2, pp. 205-210, (2008)

[5]

Burke K.E., Lamont J.T., Clostridium difficile inection: A worldwide disease, Gut Liver, 8, 1, pp. 1-6, (2014)

[6]

Jen M.H., Saxena S., Bottle A., Aylin P., Pollok R.C., Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease, Aliment Pharmacol Ther, 33, 12, pp. 1322-1331, (2011)

[7]

Murthy S.K., Steinhart A.H., Tinmouth J., Austin P.C., Daneman N., Nguyen G.C., Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis, Aliment Pharmacol Ther, 36, 11-12, pp. 1032-1039, (2012)

[8]

Masclee G.M., Penders J., Jonkers D.M., Wolffs P.F., Pierik M.J., Is Clostridium difficile associated with relapse of inflammatory bowel disease? Results from a retrospective and prospective cohort study in the Netherlands, Inflamm Bowel Dis, 19, 10, pp. 2125-2131, (2013)

[9]

Hourigan S.K., Chirumamilla S.R., Ross T., Golub J.E., Rabizadeh S., Saeed S.A., Et al., Clostridium difficile carriage and serum antitoxin responses in children with inflammatory bowel disease, Inflamm Bowel Dis, 19, 13, pp. 2744-2752, (2013)

[10]

Mir S.A., Kellermayer R., Clostridium difficile infection in newly diagnosed pediatric inflammatory bowel disease in the midsouthern United States, J Pediatr Gastroenterol Nutr, 57, 4, pp. 487-488, (2013)

← 1 2 3 →